研究用フローサイトと理化学分析

世界のリサーチ分野のお客さまへ先端の検査装置のご案内です。

お問い合わせはこちら

sysmex

研究用フローサイトと理化学分析sysmex

CyFlow CD14 PE-Cy5

品番 CD565869
抗体名 Anti-Hu CD14 PE-CY5,MEM-15
包装単位 100 tests
濃度 -
容量 0.4 ml
関連製品
(アイソタイプコントロール)
Mouse IgG1 PE-Cy5 (AJ384786)
反応性|交差吸着 Human | Non-Human Primates レーザー Blue, Green, Yellow
抗原 CD14, LPS-R 最大蛍光波長 670 nm
クローン MEM-15 最大励起波長 496 nm, 565 nm
ホスト Mouse 標識/Format PE-Cy5
アイソタイプ IgG1 研究分野 Immunophenotyping
クローナリティ monoclonal 用途

Flow cytometry

Anti-Hu CD14 PE-CY5,MEM-15

特異性

The mouse monoclonal antibody MEM-15 recognizes CD14 antigen, a 53-55 kDa GPI (glycosylphosphatidylinositol)-linked membrane glycoprotein expressed on monocytes, macrophages and weakly on granulocytes; also expressed by most tissue macrophages. The antibody MEM-15 also reacts with soluble forms of CD14 found in serum and in the urine of some nephrotic patients.

抗原情報

CD14 is a 55 kDa GPI-anchored glycoprotein, constitutively expressed on the surface of mature monocytes, macrophages, and neutrophils, where serves as a multifunctional lipopolysaccharide receptor; it is also released to the serum both as a secreted and enzymatically cleaved GPI-anchored form. CD14 binds lipopolysaccharide molecule in a reaction catalyzed by lipopolysaccharide-binding protein (LBP), an acute phase serum protein. The soluble sCD14 is able to discriminate slight structural differences between lipopolysaccharides and is important for neutralization of serum allochthonous lipopolysaccharides by reconstituted lipoprotein particles. CD14 affects allergic, inflammatory and infectious processes.

利用方法

The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

保存方法

Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.

安定性情報

Do not use after expiration date stamped on vial label.

レファレンス

• Asai Y, Makimura Y, Kawabata A, Ogawa T: Soluble CD14 discriminates slight structural differences between lipid as that lead to distinct host cell activation. J·Immunol. 2007·Dec·1; 179(11):7674‑83. <·PMID:·18025213·>
• Bazil V, Horejsi V, Baudys M, Kristofova H, Strominger JL, Kostka W, Hilgert I: Biochemical characterization of a soluble form of the 53‑kDa monocyte surface antigen. Eur·J·Immunol. 1986·Dec; 16(12):1583‑9. <·PMID:·3493149·>
• Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·>
• Fernández-Real JM, Broch M, Richart C, Vendrell J, López-Bermejo A, Ricart W: CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J·Clin·Endocrinol·Metab. 2003·Apr; 88(4):1780‑4. <·PMID:·12679473·>
• Funda DP, Tucková L, Farré MA, Iwase T, Moro I, Tlaskalová-Hogenová H: CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect·Immun. 2001·Jun; 69(6):3772‑81. <·PMID:·11349042·>
• Juan TS, Hailman E, Kelley MJ, Wright SD, Lichenstein HS: Identification of a domain in soluble CD14 essential for lipopolysaccharide (LPS) signaling but not LPS binding. J·Biol·Chem. 1995·Jul·21; 270(29):17237‑42. <·PMID:·7542233·>
• Lodrup Carlsen KC, Granum B: Soluble CD14: role in atopic disease and recurrent infections, including otitis media. Curr·Allergy·Asthma·Rep. 2007·Nov; 7(6):436‑43. <·PMID:·17986374·>
• Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT: Increased phagocyte Fc gammaRI expression and improved Fc gamma‑receptor‑mediated phagocytosis after in vivo recombinant human interferon‑gamma treatment of normal human subjects. Blood. 1997·Oct·15; 90(8):3187‑94. <·PMID:·9376602·>
• Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J: Yersinia V‑antigen exploits toll‑like receptor 2 and CD14 for interleukin 10‑mediated immunosuppression. J·Exp·Med. 2002·Oct·21; 196(8):1017‑24. <·PMID:·12391013·>
• McMichael AJ, Beverley PCL, Cobbold S, et al (Eds): Leucocyte Typing III, White Cell Differentiation Antigens. Oxford·University·Press,·Oxford. 1987; 1‑1050. <·NLM·ID:·8913266·>
• Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford·University·Press,·Oxford. 1989; 1‑1820. <·NLM·ID:·8914679·>
• Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·>

Available Safety Data Sheets

CyFlow™ monoclonal antibodies SDS CA EN

Available Technical Data Sheets

CyFlow™ CD14 PE-Cy5 (MEM-15) CD565869 TDS (US)